Opinion|Videos|December 15, 2025
Why Combined Treatment of VMS and Sleep Matters for Patient Satisfaction
Author(s)Fiona C. Baker, PhD
Fact checked by: Nicole Canfora Lupo
Fiona C. Baker, PhD, discusses the interconnected nature of VMS and sleep disturbances, stressing why treating both together—and achieving rapid symptom relief—is key for patient satisfaction.
Advertisement
Episodes in this series
Fiona C. Baker, PhD, underscores the strong physiological links between vasomotor symptoms and sleep disturbances, noting that over 65% of nighttime hot flashes trigger an awakening, though many awakenings occur independently. Treating both issues together is essential because they jointly drive the quality-of-life burden in midlife women. The conversation also emphasizes that rapid onset of symptom improvement boosts patient confidence and satisfaction, particularly for those who have struggled for years.
Advertisement
Related to this article
ACOG advises against GLP-1 receptor agonists in pregnancy and recommends considering discontinuation 1 to 2 months before conception.
Joint guidance from the AHA, AAP, ACOG, and SMFM organizes cardiovascular prevention for girls and women around 4 female life stages.
Get caught up with Contemporary OB/GYN's latest coverage from The Menopause Society Annual Meeting in San Diego, California.
Hormone therapy was associated with more frequent, longer migraines in postmenopausal women, but not with greater severity or analgesic use.
NK receptor antagonists significantly improved sleep disturbance in menopausal women at 4, 12, and 24 weeks in a meta-analysis of RCTs.
Perimenopausal women who were more physically active had significantly lower symptom burden across all domains, a study of 1808 Flo app users found.
Perimenopausal women over-reported total sleep time by a mean of 35.3 minutes and under-reported wake time compared with Fitbit data.
Elinzanetant cut moderate-to-severe VMS frequency by ≥50% in 66.9% of US participants compared with 40.5% on placebo.
Advertisement
Advertisement
Trending on Contemporary OB/GYN
1
ACOG advises against GLP-1 receptor agonists during pregnancy
2
Safety Monitoring and Dosing for NK3 Antagonists in Menopause VMS
3
Susan Reed, MD, on the future of menopause research and funding
4
Matthew Nudy, MD, on estrogen and the cardiovascular system
5